By SPC Staff
The FDA approved Bkemv (eculizumab-aeeb, Amgen) as the first interchangeable biosimilar to Soliris (eculizumab, Alexion) to treat two rare diseases that cause red blood cells to break down.
Both the biosimilar and reference product are approved to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Bkemv is a monoclonal antibody that binds to the complement C5 protein, inhibiting activation of the complement system and preventing
MAY 30, 2024